Table 1.
Demographic and clinical variables for SLE patients.
Fig 1.
Detection of anti-ficolin-3 antibodies in patients with SLE.
A) Binding of anti-ficolin-3 antibodies to immobilized ficolin-3. Microtiter plates were coated with ficolin-3. Sera from SLE patients and healthy controls were added in serial dilutions. Results represent the mean +/- standard deviation. B) Anti-ficolin-3 antibodies in serum samples. Anti-ficolin-3 antibodies were measured in 48 samples from healthy controls and in 165 samples from patients with SLE. Horizontal lines in each group indicate the median values. Statistical analyses were performed by Mann-Whitney test. A, absorbance; AU, Arbitrary units.
Fig 2.
Association between anti-ficolin-3 antibodies titers, biological markers and disease activity in patients with SLE.
Association between anti-ficolin-3 titers and anti-dsDNA antibodies (A), anti-C1q antibodies (B) and ficolin-3 concentrations (C) in SLE. D) Association between anti-ficolin-3 titers and SLE Disease Activity Index (SLEDAI). Statistical analyses were performed by Spearman’s rank correlation test.
Table 2.
Associations between SLE-related clinical features of 77 patients with active SLE and titers of anti-ficolin-3, anti-C1q and anti-dsDNA antibodies.
Fig 3.
Serum anti-ficolin-3 antibodies titers in SLE patients with active disease (flare) or in disease remission.
A) Anti-ficolin-3 titers in SLE patients with active disease (SLEDAI >4) (n = 77) or in disease remission (SLEDAI ≤4) (n = 88). B) Anti-ficolin-3 titers in SLE patients with active disease with renal involvement (n = 36) or without renal involvement (n = 41). Horizontal lines in each group indicate the median values. Statistical analyses were performed by Mann-Whitney test.
Table 3.
Characteristics of SLE patients with lupus nephritis.
Table 4.
Performances of SLE biomarkers.
Table 5.
Biological characteristics of patients with active and inactive lupus nephritis.